查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284274

到 2028 年的免疫組織化學 (IHC) 市場預測 - 按產品（試劑盒、抗體、設備、試劑）、按應用（研究用途、診斷和法醫）、按最終用戶、按地區分類的全球分析

Immunohistochemistry Market Forecasts to 2028 - Global Analysis By Product (Kits, Antibody, Equipment and Reagents), Distribution channel (Research Applications, Diagnosis and Forensic) and End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球免疫組織化學染色 (IHC) 市場規模將達到 26 億美元，預計到 2028 年將達到 42.4 億美元，預計複合年增長率為8.5%。

免疫組織化學 (IHC) 對於生物標誌物開發至關重要。 免疫組織化學 (IHC) 是一種用於識別抗原和大分子細胞成分的顯微技術。 您需要可視化目標蛋白在不同細胞類型、生物週期甚至複雜組織的細胞內的存在和定位。 IHC 的最新進展包括對單個樣本中大量蛋白質的靈敏檢測以及對蛋白質-蛋白質相互作用的輕鬆檢測。 該技術可用於測試藥物和診斷各種疾病。

根據世界衛生組織 (WHO) 的情況說明書，2022 年 2 月，癌症是全球死亡的主要原因，2020 年有近 1000 萬人死亡，即近 6 人死亡。據說佔 1 人。

市場動態：

驅動程序

人口老齡化

隨著世界老年人口的迅速增加，與年齡有關的疾病的患病率預計將急劇上升。 世界其他發達國家的老齡化人口數量龐大，而且還在不斷增加。 發生感染的機會隨著年齡的增長而增加。 因此，隨著老年人口的增長，各種疾病的患病率預計將在國際範圍內上升。 這被認為是診斷免疫組織化學 (IHC) 市場的關鍵驅動力。

約束

高度集成

抗體專利到期是全球市場面臨的一個大問題。 Merck（德國）和 F. Hoffmann-La Roche（瑞士）的一些一抗正在失去專利保護。 此外，市場進入者必須應對來自世界各國政府的定價壓力不斷增加和研發產出下降等挑戰。 為了克服這些障礙，著名的市場領導者正在收購擁有獨特專利產品的中小企業。 這為這些產品進入新的全球市場提供了巨大的財務和分銷基礎。

市場機會：

新品發布會

領先的市場參與者專注於開發滿足當前需求並推動行業發展的技術。 由於推出新的免疫組織化學 (IHC) 產品來解決前面提到的問題，預計該市場將會增長。 頂級公司生產尖端產品，有望成為市場擴張的推動力。 引入這些臨床診斷標誌物可能有助於推進免疫腫瘤學癌症治療的早期藥物開發。 由於研究和開發的增加，預計在預測期內市場將快速增長。

威脅

缺乏熟練的專業人員

隨著癌症患病率的增加，對臨床應用的病理服務的需求也在增加。 大多數對癌症患者進行的測試都是使用組織病理學技術完成的。 然而，這些實驗室缺乏訓練有素的人員。 相當多的組織病理學家都到了退休年齡，只有有限數量的組織病理學家正在接受新培訓。 另一方面，實驗室面臨著以有限的人員處理不斷增加的樣本數量的壓力。

COVID-19 的影響：

COVID-19 的爆發對免疫組織化學 (IHC) 市場產生了積極影響。 這是由於全球 COVID-19 感染的流行率上升以及越來越多地使用免疫組織化學染色 (IHC) 技術檢測 COVI-19 感染。 例如，根據 2020 年 7 月發表在 Laboratory Investigation 上的一篇論文，免疫組織化學染色 (IHC) 和原位雜交 (ISH) 技術被用於檢測 SARS-CoV-2。 所有標本均為 IHC 和 ISH 陽性，而所有非 COVID-19 患者標本均為 IHC 和 ISH 陰性。 因此，冠狀病毒 (COVID-19) 大流行的影響正在對全球免疫組織化學 (IHC) 市場產生積極影響。

預計預測期內抗體場最大

由於抗體在疾病診斷和藥物測試中的重要用途，預計抗體行業將實現利潤豐厚的增長。 單克隆抗體和 Fc 融合物、抗體片段和抗體藥物偶聯物等抗體相關產品在使用方面優於所有其他產品類別。 抗體用於多種應用，包括病理學、神經病理學和血液病理學。 研究抗體越來越多地用於藥物發現也是推動抗體市場發展的主要因素。

診斷行業預計在預測期內表現出最高的複合年增長率

在預測期內，診斷部門預計將以最高複合年增長率增長。 免疫組織化學 (IHC) 檢測可用於診斷多種慢性疾病，包括自身免疫性疾病、癌症、傳染病、心血管疾病、糖尿病和腎臟疾病。 此外，慢性病患病率的增加有望推動診斷行業的發展。 此外，傳染病的高流行率和 IHC 測試有利的報銷環境也是推動該細分市場份額擴大的因素。

市場份額最高的地區

預計在預測期內，北美將佔據最大的市場份額。 北美地區的主導地位可歸因於診斷中心和實驗室越來越多地使用這種免疫組織化學 (IHC) 儀器。 此外，美國和加拿大等國家有有吸引力的報銷規定，鼓勵使用自動化設備，從而促進了北美地區 IHC 市場的增長。 此外，預計北美越來越多的癌症患者將增加對這種免疫組織化學 (IHC) 方法的需求。

複合年增長率最高的地區：

預計亞太地區在預測期內的複合年增長率最高。 亞太地區免疫組織化學 (IHC) 市場的快速增長歸因於印度、中國、韓國和新加坡等國家的經濟繁榮。 此外，印度和中國等國家有大量的患者和大量的臨床受試者作為 IHC 研發試驗的目標，這導致收入增加。 此外，慢性病的高患病率和人口的快速老齡化也是推動亞太地區免疫組織化學（IHC）行業增長的兩個因素。

主要發展：

2021 年 8 月，羅氏獲得 FDA 批准 VENTANA MMR RxDx 伴隨診斷測試，該測試基於針對 MMR 通路缺陷實體瘤的免疫組織化學染色 (IHC)。 該測試將確定符合 GSK 抗 PD1免疫療法 JEMPERLI 的患者。

2021 年 8 月，安捷倫的 PD-L1 IHC 22C3 pharmDx 檢測在歐洲獲得了 CE-IVD 認證，該檢測用於識別適合使用 KEYTRUDA 治療的食管癌患者。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球免疫組織化學 (IHC) 市場：按產品分類

  • 工具包
    • 人體組織 IHC 試劑盒
    • 用於動物組織的 IHC 試劑盒
  • 抗體
    • 一抗
    • 二抗
  • 設備
    • 組織處理系統
    • 載玻片掃描儀
    • 載玻片染色系統
    • 其他設施
  • 試劑
    • 蛋白□
    • 有機溶劑
    • 顯色底物
    • 稀釋劑
    • 組織學染色
    • 固定試劑
    • 封閉血清和試劑
    • 其他試劑

第 6 章全球免疫組織化學 (IHC) 市場：按應用

  • 研究用途
    • 藥物測試
    • 其他研究用途
  • 診斷
    • 自身免疫性疾病
    • 癌症
    • 感染
    • 腎臟疾病
    • 神經系統疾病
    • 其他診斷
  • 取證

第 7 章全球免疫組織化學 (IHC) 市場：按最終用戶分類

  • 研究和學術機構
  • 醫院和診斷實驗室
  • 其他最終用戶
    • 製藥和生物製藥公司
    • 法醫研究所
    • 首席風險官

第 8 章整體免疫組織化學 (IHC)按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第九章主要進展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第十章公司簡介

  • Agilent Technologies, Inc.
  • Abcam plc.
  • Bio SB
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Perkinelmer, Inc.
  • F hoffman La Roche
  • Eagle Biosciences, Inc.
  • CANDOR Bioscience GmbH
  • Elabscience, Inc.
  • Thermofischer Scientific Inc
  • Biogenex Laboratories
Product Code: SMRC23106

According to Stratistics MRC, the Global Immunohistochemistry Market is accounted for $2.60 billion in 2022 and is expected to reach $4.24 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Immunohistochemistry is critical for biomarker development. Immunohistochemistry is a microscopy method used to identify antigens and macromolecular cellular components. It requires visualising the presence and localisation of the target protein in various cell types, biological cycles, and even subcellular localization within complex tissues. Recent advancements in IHC include the sensitive detection of numerous proteins in a single sample and the ease of detecting protein-protein interactions. This technique can be used to test drugs and diagnose a variety of ailments.

According to the World Health Organization (WHO) Fact sheet, February 2022, cancer is a leading cause of death worldwide, and accounted for around 10 million deaths in 2020, or nearly one in six deaths.

Market Dynamics:

Driver:

Rising geriatric population

The prevalence of age-related disorders is expected to climb dramatically as the global geriatric population grows rapidly. Geriatric populations are large and growing in other industrialised economies around the world. The chance of developing infections increases proportionally with age. As a result, it is expected that the prevalence of various diseases would increase internationally as the elderly population grows. This is regarded as an important driving force in the Immunohistochemistry (IHC) market for diagnostic applications.

Restraint:

High degree of consolidation

Antibody patent expiration is a major issue for the global market. Some Merck (Germany) and F. Hoffmann-La Roche AG (Switzerland) primary antibodies are about to lose patent protection. Furthermore, market participants must deal with challenges such as growing price pressure from governments around the world and reduced R&D output. To overcome these barriers, prominent market leaders are acquiring smaller and mid-sized firms with unique patented products. This provides a huge financial and distribution platform for these products to enter new global markets.

Opportunity:

New product launches

Key market leaders focusing on technological developments in response to current needs would boost industry development. The market is expected to grow due to the launch of new immunohistochemistry products to address the previously mentioned issues. The top companies are producing cutting-edge goods that are expected to drive market expansion. The introduction of these clinical diagnostic markers might help to advance early-stage drug development for cancer treatment in immuno-oncology. The market would grow quicker throughout the predicted period due to increased R&D.

Threat:

Dearth of skilled professionals

As the prevalence of cancer has increased, so has the demand for pathology services for clinical applications. The majority of examinations conducted on cancer patients are performed using histopathology technologies. However, there is a shortage of trained personnel in these laboratories. A considerable number of histopathologists have reached retirement age, and only a limited number of new histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing quantity of specimens with restricted personnel.

COVID-19 Impact:

The COVID-19 outbreak has had a favourable influence on the immunohistochemistry market, owing to an increase in the prevalence of COVID-19 infections worldwide and an increase in the usage of immunohistochemistry techniques for the detection of COVI-19 infections. For example, immunohistochemistry (IHC) and in situ hybridization (ISH) techniques are employed to detect SARS-CoV-2, according to a July 2020 paper published in Laboratory Investigation. All samples were IHC and ISH positive, whereas all specimens from non-COVID-19 patients were IHC and ISH negative. As a result, the impact of the coronavirus (COVID-19) pandemic has remained positive for the global immunohistochemistry (IHC) market.

The antibody segment is expected to be the largest during the forecast period

The antibody segment is estimated to have a lucrative growth, due to the vital usage of antibodies in disease diagnosis and drug testing. Monoclonal antibodies and antibody-related goods such as Fc-fusion, antibody fragments, and antibody-drug conjugates have surpassed all other product classes in terms of usage rate. The antibodies are used in a variety of applications including pathology, neuropathology, and hematopathology. The increasing usage of research antibodies for drug discovery is another major factor driving the development of the antibodies market.

The diagnosis segment is expected to have the highest CAGR during the forecast period

The diagnosis segment is anticipated to witness the highest CAGR growth during the forecast period. Immunohistochemistry tests can be used to diagnose a variety of chronic disorders, including autoimmune diseases, cancer, infectious diseases, cardiovascular diseases, diabetes mellitus, and nephrological diseases. Furthermore, the growing prevalence of chronic disorders is expected to fuel the diagnostics industry. The majority of infectious diseases and the favourable reimbursement environment for IHC tests are additional factors driving the segment's market share growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. The dominance of the North American region can be attributable to the growing use of this immunohistochemistry equipment in diagnostic centres and laboratories. Furthermore, attractive reimbursement regulations in countries like as the United States and Canada encourage the use of automated devices, which helps the growth of the IHC market in the North American region. Additionally, an increase in the number of cancer patients from North American countries is expected to increase the need for these immunohistochemical approaches.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The rapid increase of the Asia-Pacific immunohistochemistry market can be attributed to the economic prosperity of nations such as India, China, South Korea, and Singapore. Furthermore, a big patient pool in countries such as India and China provides a significant number of clinical subjects for IHC R&D tests, leading in revenue growth. Aside from these, the high prevalence of chronic diseases and the rapid ageing of the population are two additional factors driving the growth of the Asia-Pacific Immunohistochemistry Industry.

Key players in the market:

Some of the key players profiled in the Immunohistochemistry Market include Agilent Technologies, Inc., Abcam plc., Bio SB, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, Perkinelmer, Inc., F hoffman La Roche, Eagle Biosciences, Inc., CANDOR Bioscience GmbH, Elabscience, Inc., Thermofischer Scientific Inc and Biogenex Laboratories.

Key Developments:

In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK's anti-PD1 immunotherapy, JEMPERLI.

In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.

Products Covered:

  • Kits
  • Antibody
  • Equipment
  • Reagents

Applications Covered:

  • Research Applications
  • Diagnosis
  • Forensic

End Users Covered:

  • Research Institutes and Academic Institutes
  • Hospital and Diagnostic Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunohistochemistry Market, By Product

  • 5.1 Introduction
  • 5.2 Kits
    • 5.2.1 IHC Kits for Human Tissue
    • 5.2.2 IHC Kits for Animal Tissue
  • 5.3 Antibody
    • 5.3.1 Primary Antibodies
    • 5.3.2 Secondary Antibodies
  • 5.4 Equipment
    • 5.4.1 Tissue Processing Systems
    • 5.4.2 Slide Scanners
    • 5.4.3 Slide staining Systems
    • 5.4.4 Other Equipments
  • 5.5 Reagents
    • 5.5.1 Proteolytic Enzymes
    • 5.5.2 Organic Solvents
    • 5.5.3 Chromogenic Substrates
    • 5.5.4 Diluents
    • 5.5.5 Histological Stains
    • 5.5.6 Fixation Reagents
    • 5.5.7 Blocking Sera and Reagents
    • 5.5.8 Other Reagents

6 Global Immunohistochemistry Market, By Application

  • 6.1 Introduction
  • 6.2 Research Applications
    • 6.2.1 Drug Testing
    • 6.2.2 Other Research Applications
  • 6.3 Diagnosis
    • 6.3.1 Autoimmune diseases
    • 6.3.2 Cancer
    • 6.3.3 Infectious diseases
    • 6.3.4 Nephrological diseases
    • 6.3.5 Neurological diseases
    • 6.3.6 Other Diagnosis
  • 6.4 Forensic

7 Global Immunohistochemistry Market, By End User

  • 7.1 Introduction
  • 7.2 Research Institutes and Academic Institutes
  • 7.3 Hospital and Diagnostic Labs
  • 7.4 Other End Users
    • 7.4.1 Pharma & Biopharma Companies
    • 7.4.2 Forensic Laboratories
    • 7.4.3 CROs

8 Global Immunohistochemistry Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Agilent Technologies, Inc.
  • 10.2 Abcam plc.
  • 10.3 Bio SB
  • 10.4 Bio-Rad Laboratories, Inc.
  • 10.5 Cell Signaling Technology, Inc.
  • 10.6 Danaher Corporation
  • 10.7 F. Hoffmann-La Roche Ltd.
  • 10.8 Merck KGaA
  • 10.9 Perkinelmer, Inc.
  • 10.10 F hoffman La Roche
  • 10.11 Eagle Biosciences, Inc.
  • 10.12 CANDOR Bioscience GmbH
  • 10.13 Elabscience, Inc.
  • 10.14 Thermofischer Scientific Inc
  • 10.15 Biogenex Laboratories

List of Tables

  • Table 1 Global Immunohistochemistry Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Immunohistochemistry Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global Immunohistochemistry Market Outlook, By Kits (2020-2028) ($MN)
  • Table 4 Global Immunohistochemistry Market Outlook, By IHC Kits for Human Tissue (2020-2028) ($MN)
  • Table 5 Global Immunohistochemistry Market Outlook, By IHC Kits for Animal Tissue (2020-2028) ($MN)
  • Table 6 Global Immunohistochemistry Market Outlook, By Antibody (2020-2028) ($MN)
  • Table 7 Global Immunohistochemistry Market Outlook, By Primary Antibodies (2020-2028) ($MN)
  • Table 8 Global Immunohistochemistry Market Outlook, By Secondary Antibodies (2020-2028) ($MN)
  • Table 9 Global Immunohistochemistry Market Outlook, By Equipment (2020-2028) ($MN)
  • Table 10 Global Immunohistochemistry Market Outlook, By Tissue Processing Systems (2020-2028) ($MN)
  • Table 11 Global Immunohistochemistry Market Outlook, By Slide Scanners (2020-2028) ($MN)
  • Table 12 Global Immunohistochemistry Market Outlook, By Slide staining Systems (2020-2028) ($MN)
  • Table 13 Global Immunohistochemistry Market Outlook, By Other Equipments (2020-2028) ($MN)
  • Table 14 Global Immunohistochemistry Market Outlook, By Reagents (2020-2028) ($MN)
  • Table 15 Global Immunohistochemistry Market Outlook, By Proteolytic Enzymes (2020-2028) ($MN)
  • Table 16 Global Immunohistochemistry Market Outlook, By Organic Solvents (2020-2028) ($MN)
  • Table 17 Global Immunohistochemistry Market Outlook, By Chromogenic Substrates (2020-2028) ($MN)
  • Table 18 Global Immunohistochemistry Market Outlook, By Diluents (2020-2028) ($MN)
  • Table 19 Global Immunohistochemistry Market Outlook, By Histological Stains (2020-2028) ($MN)
  • Table 20 Global Immunohistochemistry Market Outlook, By Fixation Reagents (2020-2028) ($MN)
  • Table 21 Global Immunohistochemistry Market Outlook, By Blocking Sera and Reagents (2020-2028) ($MN)
  • Table 22 Global Immunohistochemistry Market Outlook, By Other Reagents (2020-2028) ($MN)
  • Table 23 Global Immunohistochemistry Market Outlook, By Application (2020-2028) ($MN)
  • Table 24 Global Immunohistochemistry Market Outlook, By Research Applications (2020-2028) ($MN)
  • Table 25 Global Immunohistochemistry Market Outlook, By Drug Testing (2020-2028) ($MN)
  • Table 26 Global Immunohistochemistry Market Outlook, By Other Research Applications (2020-2028) ($MN)
  • Table 27 Global Immunohistochemistry Market Outlook, By Diagnosis (2020-2028) ($MN)
  • Table 28 Global Immunohistochemistry Market Outlook, By Autoimmune diseases (2020-2028) ($MN)
  • Table 29 Global Immunohistochemistry Market Outlook, By Cancer (2020-2028) ($MN)
  • Table 30 Global Immunohistochemistry Market Outlook, By Infectious diseases (2020-2028) ($MN)
  • Table 31 Global Immunohistochemistry Market Outlook, By Nephrological diseases (2020-2028) ($MN)
  • Table 32 Global Immunohistochemistry Market Outlook, By Neurological diseases (2020-2028) ($MN)
  • Table 33 Global Immunohistochemistry Market Outlook, By Other Diagnosis (2020-2028) ($MN)
  • Table 34 Global Immunohistochemistry Market Outlook, By Forensic (2020-2028) ($MN)
  • Table 35 Global Immunohistochemistry Market Outlook, By End User (2020-2028) ($MN)
  • Table 36 Global Immunohistochemistry Market Outlook, By Research Institutes and Academic Institutes (2020-2028) ($MN)
  • Table 37 Global Immunohistochemistry Market Outlook, By Hospital and Diagnostic Labs (2020-2028) ($MN)
  • Table 38 Global Immunohistochemistry Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 39 Global Immunohistochemistry Market Outlook, By Pharma & Biopharma Companies (2020-2028) ($MN)
  • Table 40 Global Immunohistochemistry Market Outlook, By Forensic Laboratories (2020-2028) ($MN)
  • Table 41 Global Immunohistochemistry Market Outlook, By CROs (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.